| Convenient self-administered treatment regimen (once-monthly subcutaneous injections) |
| Significantly reduces annualized relapse rate, MRI-detected lesion activity and disability progression compared with teriflunomide |
| Generally manageable tolerability profile; AESIs include infections and injection-related reactions |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.